ABCG2 Inhibitor Compounds for Controlling PPIX Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are lacking, and existing photodynamic therapy and fluorescence-guided resection methods are limited by the pharmacokinetic properties of protoporphyrin IX (PPIX), necessitating improved mechanisms for managing PPIX accumulation and photoreactivity.
Innovation Solution
Development of amido pyrido[3,4-b]indole-1,4-dione compounds that inhibit the ABCG2 protein, reducing PPIX efflux from cells and enhancing fluorescence-guided resection and photodynamic therapy by altering PPIX distribution and metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If photodynamic therapy or fluorescence-guided resection is used, then therapeutic outcome or imaging capability is improved, but the method is limited by the pharmacokinetic properties of PPIX
Solution Approach 1:
The patent introduces ABCG2 inhibitors as intermediary substances that mediate between PPIX accumulation and therapeutic efficacy. These inhibitors act as modulators that enhance PPIX retention in cells, thereby improving photodynamic therapy outcomes and fluorescence imaging capabilities without directly altering PPIX itself.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of PPIX by inhibiting its efflux transport. By using ABCG2 inhibitors, the concentration and distribution of PPIX in target cells are modified, extending its half-life and enhancing its therapeutic and imaging properties.
2Reliability
If PPIX accumulates in cells, then fluorescence-guided resection and photodynamic therapy efficacy are improved, but skin sensitivity to sunlight increases
Solution Approach 1:
The patent applies local quality by selectively accumulating PPIX in specific target cells (such as cancer cells or porphyria-affected cells) through ABCG2 inhibition. This localized accumulation enhances therapy efficacy in the target area while managing skin sensitivity through controlled PPIX distribution.
Solution Approach 2:
The patent converts the harmful effect of PPIX-induced skin sensitivity into a beneficial selective phototoxic effect. By using ABCG2 inhibitors to accumulate PPIX in target cells, the harmful photoreactivity is redirected to specifically harm only the intended target cells during photodynamic therapy.
3Reliability
If ABCG2 inhibitor compounds are administered, then PPIX efflux is reduced and therapy efficacy is enhanced, but device complexity increases
Solution Approach 1:
The patent develops ABCG2 inhibitor compounds that serve multiple functions: they inhibit PPIX efflux, enhance photodynamic therapy efficacy, and improve fluorescence imaging capabilities. This multi-functionality reduces the need for separate agents, thereby managing overall treatment complexity.
Solution Approach 2:
The patent optimizes the pharmacological parameters of the ABCG2 inhibitor compounds to achieve effective PPIX efflux inhibition with manageable structural complexity. By tuning molecular properties such as binding affinity and selectivity, the compounds achieve therapeutic efficacy without excessive structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce skin sensitivity to sunlight, alleviate symptoms, and enhance therapeutic outcomes in EPP and XLP by inhibiting ABCG2-mediated PPIX efflux, improving photodynamic therapy efficacy and fluorescence imaging.
Implementation Method 1
Compounds provided herein may have inhibitory activity against ABCG2 protein (also referred to as BCRP), a transporter of protoporphyrin IX (PPIX)
Implementation Method 2
Because PPIX is a fluorophore, the locations of cancerous tissue can be imaged, for example during a surgery
Implementation Method 3
By shining a light on tissue that has been treated with PPIX or a PPIX precursor such as ALA, those cells that differentially produced PPIX will be harmed or destroyed by PPIX-induced reactive oxygen species
Data Source
AI summary
Provided herein are compounds, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions in the treatment of ABCG2-mediated diseases, disorders, and conditions such as porphyrias, wherein the compound is according to formula (I):or a pharmaceutically acceptable salt thereof, where subscript n, R1, and R2 are each as described herein.